trending Market Intelligence /marketintelligence/en/news-insights/trending/m9v0yejcpy_jyzm2wootrw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US PTO gives DelMar notice of allowance for brain cancer drug

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


US PTO gives DelMar notice of allowance for brain cancer drug

DelMar Pharmaceuticals Inc. received a notice of allowance from the U.S. Patent and Trademark Office for its patent application involving VAL-083, a potential brain cancer treatment.

VAL-083 is under preparation for a phase 3 clinical trial in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer.

The patent has also been granted in Australia and is being prosecuted in other international jurisdictions as part of more than 100 patent filings from 13 patent families representing claims covering VAL-083 until 2036.

DelMar expects the U.S. patent to be issued in early 2017.